With an aim to better explain how a drug’s benefits and risks inform regulatory decision-making, FDA said Friday it expects to draft guidance on the topic by the end of June 2020. As outlined in the ...
The US Food and Drug Administration (FDA) has published a new report calling for a new drug regulatory decision-making paradigm for risk-benefit assessments, rejecting calls for a quantitative-only ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する